title: Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.
abstract: The aim of this study was to predict cardiovascular complications in patients with prostatic cancer treated with oestrogen. A randomised prospective study of oestrogen therapy versus orchiectomy was performed. Patients with pre-existing cardiovascular morbidity were excluded (16%). Prior to the initiation of therapy, patients were subjected to exercise stress tests, physiological evaluation of peripheral circulation, blood volume estimation, chest X-ray, blood test, including hormones, lipoproteins, and antithrombin III, and a physical examination and history by a cardiologist. The oestrogen treatment and the orchiectomy group did not differ with regard to these pretreatment variables; 25% of the patients given oestrogen therapy had cardiovascular complications during the initial treatment year compared with none in the orchiectomy group. Three statistical discriminating techniques were employed and they allowed us to identify 2 strong discriminating variables for cardiovascular complications if oestrogen therapy is instituted in patients with prostatic cancer but without overt clinical cardiovascular disease. These 2 discriminators were luteinising hormone (LH) and ST-segment depression during exercise. This means that a patient with ST-segment depression during an exercise test and/or a high luteinising hormone concentration should not be treated with oestrogen.
authors.affiliation: Department of Medicine, Huddinge Hospital, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Henriksson
authors.forename: O
authors.initials: O
authors.lastname: Edhag
authors.forename: A
authors.initials: A
authors.lastname: Eriksson
authors.forename: S E
authors.initials: SE
authors.lastname: Johansson
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011897:Random Allocation; D012307:Risk Factors
chemical_list: D045166:Estradiol Congeners; D004997:Ethinyl Estradiol; D004958:Estradiol; C008958:polyestradiol phosphate